Authors: | Gordon, J. K.; Magid, S. K.; Maki, R. G.; Fleisher, M.; Berman, E. |
Article Title: | Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec™) |
Abstract: | Imatinib mesylate is used with increasing frequency and duration for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), and other neoplastic conditions. Although muscular complaints are common, elevations of creatine kinase (CK) are listed as <1% in the product label. We describe here a case of rhabdomyolysis likely related to imatinib as well as the results of a prospective evaluation of CK levels in a cohort of patients on imatinib for CML or GIST. We found a high prevalence of CK abnormalities in this group and believe that CKs should be monitored during therapy with imatinib. © 2009 Elsevier Ltd. |
Keywords: | adult; cancer chemotherapy; aged; middle aged; young adult; case-control studies; clinical feature; anamnesis; case report; dose response; drug dose reduction; drug safety; drug withdrawal; side effect; antineoplastic agents; imatinib; gastrointestinal stromal tumors; edema; cohort studies; myalgia; differential diagnosis; steroid; dasatinib; chronic myeloid leukemia; pyrimidines; drug dose escalation; creatine kinase; piperazines; drug dose titration; up-regulation; drug substitution; autoimmune disease; leukemia, myelogenous, chronic, bcr-abl positive; creatine kinase blood level; myopathy; adverse effect; muscular disease; rhabdomyolysis; arm swelling; muscular diseases |
Journal Title: | Leukemia Research |
Volume: | 34 |
Issue: | 6 |
ISSN: | 0145-2126 |
Publisher: | Elsevier Ltd |
Date Published: | 2010-06-01 |
Start Page: | 827 |
End Page: | 829 |
Language: | English |
DOI: | 10.1016/j.leukres.2009.11.002 |
PUBMED: | 19963273 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 20 April 2011" - "CODEN: LERED" - "Source: Scopus" |